A Breakthrough-No Deaths from Cervical Cancer in Young Women in England

England recorded zero deaths from cervical cancer among women ages 20-24 over a five-year period, according to a study from Queen Mary University of London. This outcome is attributed to the widespread adoption of the human papillomavirus (HPV) vaccine, which protects against high-risk virus types that cause cancer.

Impact of HPV Vaccination on Cervical Cancer Deaths in England

Researchers from Queen Mary University of London analyzed health records to determine if the national vaccination program reduced cervical cancer mortality. The data showed no deaths in the 20-24 age group for five consecutive years. Without the vaccine, researchers estimated that approximately 23 women in this age bracket would have died from the disease during that time, according to the study.

The vaccine also reduced mortality for women aged 25-34. Researchers estimate the vaccination program prevented about 200 deaths within that specific group during the study period.

England began offering the HPV vaccine to 12- and 13-year-old girls in 2008, two years after the vaccine received approval. Between 80% and 90% of girls in that age group were vaccinated at the time of the rollout. The government also implemented a catch-up program for girls aged 14-18.

Future Projections for Cancer Elimination

The first cohort of young women who received the vaccine have now entered their early 30s. Professor Peter Sasieni, the lead researcher on the study, told the BBC that the 200 prevented deaths documented so far represent the tip of the iceberg.

Sasieni stated to the BBC, As vaccinated generations grow older, we’ll see many more lives saved from cervical cancer. He believes that as these vaccinated women age, the program could prevent as many as 18,000 deaths.

HPV Risks and Vaccination Guidelines

Human papillomavirus is a common sexually transmitted infection that most sexually active people will contract. While most infections are cleared by the immune system without causing health issues, certain high-risk types of HPV can lead to cancers of the cervix, vagina, vulva, anus, head, neck, and throat.

The HPV vaccine provides protection against nine of these high-risk types. In the United States, the Centers for Disease Control and Prevention (CDC) recommends the vaccine for adolescents at age 11 and 12, though it can be administered as early as age 9. The CDC recommends the vaccine for all adolescents regardless of sex or gender assigned at birth.

Current CDC guidelines include catch-up vaccinations for individuals 26 and under who missed the vaccine during their teenage years. The vaccine is approved for use in people up to age 45.

Vaccination Trends and Supplemental Screening

Despite the efficacy shown in the England study, HPV vaccination rates have declined in both the United States and England. Both nations experienced a drop in vaccination numbers during the pandemic and have not yet returned to previous levels.

Public health officials emphasize that vaccines are one part of a broader prevention strategy. Regular cervical cancer screening remains necessary to identify HPV infections and cellular changes in the cervix before they progress into cancer.

Recent developments in screening include the FDA approval of the Teal Wand, a self-collection device for HPV testing that allows users to collect samples at home. Additionally, organizations including the American Cancer Society (ACS), the American College of Obstetricians and Gynecologists (ACOG), and the Health Resources and Services Administration (HRSA) have endorsed guidelines that include the use of self-collected samples for screening.